^
    CANCER:

    Ovarian Serous Adenocarcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + pegylated liposomal doxorubicin
    1
    PD1 inhibitor
    pembrolizumab
    2
    PARP inhibitor
    olaparib
    3
    VEGF-A inhibitor
    bevacizumab
    4
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    5
    MEK inhibitor
    trametinib
    6
    WEE1 inhibitor
    AZD1775
    7
    ALK inhibitor
    crizotinib
    8
    Selective estrogen receptor degrader
    fulvestrant
    9
    Aromatase inhibitor, Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel + letrozole
    10
    Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel
    11
    Aromatase inhibitor, Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + letrozole + pegylated liposomal doxorubicin
    12
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor, FAK inhibitor
    VS-6766 + VS-6063
    VS-6766 + VS-4718
    13
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    14
    MEK inhibitor, PTPN11 inhibitor
    binimetinib + PF-07284892
    15
    Chk1 inhibitor, Chk2 inhibitor, PARP inhibitor
    olaparib + ACR-368
    16
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    binimetinib + encorafenib
    17
    Tubulin polymerization promoter
    carboplatin
    18
    DNA synthesis inhibitor
    cisplatin
    19
    FAK inhibitor
    VS-4718
    20
    Chk1 inhibitor, Chk2 inhibitor, PI3K inhibitor, mTOR inhibitor
    ACR-368 + LY3023414
    21
    pan-RAF inhibitor
    LY3009120
    No biomarker
    BRCA1 mutation
    KRAS G12D
    KRAS G12V
    KRAS G12A
    BRCA1 deletion
    KRAS wild-type
    BRCA2 mutation
    BRCA2 deletion
    BRAF V600E
    BRAF L485-P490 deletion
    SERPINE1 expression
    GOPC-ROS1 fusion
    ER Y537N
    TMB-H + MSH6 F1088fs
    Choline elevation
    PRMT1 underexpression
    RAF1 V207G